ApoB vs LDL Cholesterol: The Number That Predicts Risk
Quick Summary Every atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule, so ApoB is a direct count of the particles capable of entering and damaging the artery wall. LDL cholesterol measures the cholesterol cargo inside those particles, not how many particles there are. The two usually agree, and when they disagree the particle count […]
Cystatin C vs Creatinine: Kidney Tests and Muscle Mass
Quick Summary Serum creatinine is a breakdown product of muscle. The more muscle you carry, the higher your creatinine runs at any given true filtration rate. That means creatinine-based eGFR systematically underestimates kidney function in heavily muscled people, and can produce a chronic kidney disease label in someone with normal kidneys. Cystatin C is produced […]
Biohackers Unite Online to Combat Coronavirus Pandemic
When the coronavirus pandemic swept across the globe in early 2020, the biohacking community demonstrated what self-directed health optimization is truly about. As reported by The Guardian in March 2020, biohackers worldwide began collaborating online to develop innovative solutions to combat the virus—a movement that exemplifies the same pioneering spirit that Tony Huge has championed […]
Super-Rich Biohackers: Tim Gurner & Elite Longevity Protocols
The world of biohacking has evolved from a fringe movement into a billion-dollar industry embraced by the ultra-wealthy, with Australian property mogul Tim Gurner becoming the latest high-profile figure to publicly discuss his extensive anti-aging regimen. According to recent reports from The Guardian, Gurner and a growing cohort of super-rich “grinders” are investing astronomical sums […]
Common Supplement Reverses Aging in Groundbreaking Study
In a development that has captured the attention of the biohacking and longevity optimization community, researchers have documented the first successful reversal of premature aging in humans using a widely available supplement. The landmark clinical trial, recently reported by ScienceDaily, represents a significant milestone in the quest for age-reversal interventions that Tony Huge and the […]
UBX1325: The Senolytic That Nearly Proved It
UBX1325 (Foselutoclax): The Senolytic That Got Closest to Proving It — and What It Still Didn’t Prove Quick Summary UBX1325 (foselutoclax) is an investigational small-molecule BCL-xL inhibitor injected directly into the eye. It kills senescent cells by blocking the survival protein they lean on. It was tested against a real drug in a real head-to-head […]
Obicetrapib: The CETP Inhibitor That Came Back
Obicetrapib: The CETP Inhibitor That Came Back From the Dead Quick Summary Obicetrapib is an investigational once-daily oral CETP inhibitor, not approved for general prescription anywhere. Regulatory decisions in Europe, the UK and Switzerland were expected in the second half of 2026; there is no US approval. The CETP class was written off twice. Torcetrapib […]
Zoledronic Acid: Bone Density and the Geroprotector Case
Zoledronic Acid: Bone Density, and the Case For and Against It as a Geroprotector Quick Summary A nitrogen-containing bisphosphonate given as an IV infusion by a clinician. It inhibits farnesyl pyrophosphate synthase in osteoclasts, shutting down bone resorption long after a single dose. The fracture data are strong: in HORIZON-PFT, three annual infusions cut vertebral […]
Canakinumab and CANTOS: What Targeting IL-1B Achieved
Canakinumab and CANTOS: What Happened When Someone Finally Tested “Inflammaging” Head-On Quick Summary Canakinumab is a monoclonal antibody that neutralizes interleukin-1β (IL-1β), the cytokine released downstream of the NLRP3 inflammasome. It is FDA-approved for rare autoinflammatory conditions and gout flares — not for cardiovascular prevention or longevity. CANTOS randomized 10,061 post-heart-attack patients with hsCRP ≥2 […]
Low-Dose Colchicine for Heart Risk: What Trials Show
Low-Dose Colchicine for Heart Risk: What Trials Show Quick Summary June 2023: the FDA approved colchicine 0.5 mg (Lodoco) to reduce risk of MI, stroke, coronary revascularization and cardiovascular death in adults with atherosclerotic disease or multiple risk factors — the first anti-inflammatory approved for that purpose. LoDoCo2 (5,522 chronic coronary disease patients): primary composite […]